Sponsor:
Eli Lilly and Company
Code:
NCT07867340
Conditions
C-Reactive Protein
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Accepted
Interventions
LY5625573
Midazolam
Placebo
Brief summary:
Conditions
C-Reactive Protein
Study ID
NCT07867340
Start date
Sep 29, 2026
Status verified date
Nov, 2026
Completion date
Jan, 2027
Anticipated
Primary completion date
Jan, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Accepted
Enrollment
96 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Basic Science
Arms
experimental: LY5625573 Part A - Single Dose Healthy
placebo comparator: Placebo Part A - Single Dose Healthy
experimental: LY5625573 + Midazolam Part B - Multiple Dose Healthy
placebo comparator: Placebo + Midazolam Part B - Multiple Dose Healthy
experimental: LY5625573 Part C - Multiple Dose Elevated hsCRP
placebo comparator: Placebo Part C - Multiple Dose Elevated hsCRP
experimental: LY5625573 Part D - Healthy Japanese
placebo comparator: Placebo Part D - Healthy Japanese
experimental: LY5625573 Part E - Healthy Chinese
placebo comparator: Placebo Part E - Healthy Chinese
Interventions
LY5625573
Midazolam
Placebo
Primary outcome measure
Central contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.comLocations
Fortrea Clinical Research Unit
Recruiting
Dallas, Texas, United States, 75247
Contacts
Principal Investigator:
Gene Voskuhl
Sponsor
Eli Lilly and Company
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.